ArticlePreventive medicine reports2025
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trends in product characteristics of disposable e-cigarettes sold by US online stores between 2022 and 2024.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Oxidative Stress as a Potential Mechanistic Bridge Between Electronic Cigarette Components and Chronic Disease: A Combined Narrative and Bibliometric Analysis.Antioxidants (Basel, Switzerland) · 2026Review
- [Vaping-associated central retinal vein occlusion].Die Ophthalmologie · 2026Article
- Marketing for Sensa: A novel "zero nicotine vapor product" from a major tobacco company.Research square · 2024Article
Corrections and comments
- Erratum issuedCorrigendum to "2025
- Update of
Authors and funding
7 authors.
Funding
Abstract
Objective: Nicotine concentration, form (salt vs. freebase), and type (synthetic vs. tobacco-derived) are key characteristics of e-cigarettes that manufacturers manipulate. Marketing claims such as "tobacco-free" may attract new consumers and increase product use intentions. This study aimed to monitor the nicotine claims of e-cigarettes and assess their market proportions in the U.S. Methods: We analyzed e-cigarette sales and nicotine marketing claims using Nielsen ScanTrack data from U.S. brick-and-mortar stores. Market proportion was calculated as the ratio of unit sales of each nicotine claim category to the total unit sales of e-cigarettes between 12/24/2023 and 1/20/2024. Results: Nicotine claims were categorized into six groups, with the following market proportion: nicotine (77 %), nicotine salt (10.1 %), synthetic nicotine (2.2 %), zero tobacco or tobacco-free (2.2 %), zero nicotine or nicotine-free (0.03 %), and no claim (8.7 %). The market proportion of each category of nicotine concentration was as follows (market proportion in parentheses): 0 % (0.04 %), 0.1 to less than 2 % (2.9 %), 2 to less than 5 % (16.2 %), 5 % or higher (73.0 %), and unspecified (7.9 %). Conclusions: The market proportion of products that explicitly used nicotine salt, synthetic nicotine, or tobacco-free claims was notable. Products with high nicotine concentration (5 % or higher) dominated the market, highlighting their continued popularity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.